Assessment of shoulder position variation and its impact on IMRT and VMAT doses for head and neck cancer

<p>Abstract</p> <p>Background</p> <p>For radiotherapy of the head and neck, 5-point mask immobilization is used to stabilize the shoulders. Still, the daily position of the shoulders during treatment may be different from the position in the treatment plan despite correct isocenter setup. The purpose of this study was to determine the interfractional displacement of the shoulders relative to isocenter over the course of treatment and the associated dosimetric effect of this displacement.</p> <p>Methods</p> <p>The extent of shoulder displacements relative to isocenter was assessed for 10 patients in 5-point thermoplastic masks using image registration and daily CT-on-rails scans. Dosimetric effects on IMRT and VMAT plans were evaluated in Pinnacle based on simulation CTs modified to represent shoulder shifts between 3 and 15 mm in the superior-inferior, anterior-posterior, and right-left directions. The impact of clinically observed shoulder shifts on the low-neck dose distributions was examined.</p> <p>Results</p> <p>Shoulder motion was 2-5 mm in each direction on average but reached 20 mm. Superior shifts resulted in coverage loss, whereas inferior shifts increased the dose to the brachial plexus. These findings were generally consistent for both IMRT and VMAT plans. Over a course of observed shifts, the dose to 99% of the CTV decreased by up to 101 cGy, and the brachial plexus dose increased by up to 72 cGy.</p> <p>Conclusions</p> <p>he position of the shoulder affects target coverage and critical structure dose, and may therefore be a concern during the setup of head and neck patients, particularly those with low neck primary disease.</p

Monitor unit calculations for external photon and electron beams: Report of the AAPM Therapy Physics Committee Task Group No. 71

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/134882/1/mp4244.pd

Development and implementation of an anthropomorphic pediatric spine phantom for the assessment of craniospinal irradiation procedures in proton therapy

Purpose: To design an anthropomorphic pediatric spine phantom for use in the evaluation of proton therapy facilities for clinical trial participation by the Imaging and Radiation Oncology Core (IROC) Houston QA Center (formerly RPC).Methods: This phantom was designed to perform an end-to-end audit of the proton spine treatment process, including simulation, dose calculation by the treatment planning system (TPS), and proton treatment delivery. The design incorporated materials simulating the thoracic spinal column of a pediatric patient, along with two thermoluminescent dosimeter (TLD)-100 capsules and radiochromic film embedded in the phantom for dose evaluation. Fourteen potential materials were tested to determine relative proton stopping power (RSP) and Hounsfield unit (HU) values. Each material was CT scanned at 120 kVp, and the RSP was obtained from depth ionization scans using the Zebra multi-layer ion chamber (MLIC) at two energies: 160 MeV and 250 MeV. To determine tissue equivalency, the measured RSP for each material was compared to the RSP calculated by the Eclipse TPS for a given HU.Results: The materials selected as bone, tissue, and cartilage substitutes were Techron HPV Bearing Grade (Boedeker Plastics, Inc.), solid water, and blue water, respectively. The RSP values did not differ by more than 1.8% between the two energies. The measured RSP for each selected material agreed with the RSP calculated by the Eclipse TPS within 1.2%.Conclusion: An anthropomorphic pediatric proton spine phantom was designed to evaluate proton therapy delivery. The inclusion of multiple tissue substitutes increases heterogeneity and the level of difficulty for institutions to successfully treat the phantom. The following attributes will be evaluated: absolute dose agreement, distal range, field width, junction match and right/left dose profile alignment. The phantom will be tested at several institutions using a 5% dose agreement criterion, and a 5%/3mm gamma analysis criterion for the film planes.--------------------------------------Cite this article as: Lewis DJ, Summers PA, Followill DS, Sahoo N, Mahajan A, Stingo FC, Kry SF. Development and implementation of an anthropomorphic pediatric spine phantom for the assessment of craniospinal irradiation procedures in proton therapy. Int J Cancer Ther Oncol 2014; 2(2):020227. DOI: 10.14319/ijcto.0202.2

Evaluation of three commercial metal artifact reduction methods for CT simulations in radiation therapy

Purpose: To evaluate the success of three commercial metal artifact reduction methods (MAR) in the context of radiation therapy treatment planning.Methods: Three MAR strategies were evaluated: Philips O-MAR, monochromatic imaging using Gemstone Spectral Imaging (GSI) dual energy CT, and monochromatic imaging with metal artifact reduction software (GSI-MARs). The Gammex RMI 467 tissue characterization phantom with several metal rods and two anthropomorphic phantoms (pelvic phantom with hip prosthesis and head phantom with dental fillings), were scanned with and without metals (baseline). Each MAR method was evaluated based on CT number accuracy, metal size accuracy, and reduction in the severity of streak artifacts. CT number difference maps between the baseline and metal scan images were calculated, and the severity of streak artifacts was quantified using the percentage of pixels with &gt; 40 HU error (“bad pixels”).Results: Philips O-MAR generally reduced HU errors in the RMI phantom. However, increased errors and induced artifacts were observed for lung materials. GSI monochromatic 70keV images generally showed similar HU errors as conventional 120kVp imaging, while 140keV images reduced HU errors. All the imaging techniques represented the diameter of a stainless steel rod to within ±1.6mm (2 pixels). For the hip prosthesis, O-MAR reduced the average % bad pixels from 47% to 32%. For GSI 140keV imaging, the % bad pixels was reduced from 37% to 29% compared to 120kVp imaging, and GSI-MARs further reduced it to 12%. For the head phantom, none of the MAR methods was particularly successful.Conclusion: O-MAR resulted in consistent artifact reduction but exhibited induced artifacts for metals located near lung tissue. GSI imaging at 140keV gave consistent reduction in HU errors and severity of artifacts. GSI-MARs at 140keV was the most successful MAR method for the hip prosthesis but exhibited induced artifacts at the edges of metals in some cases.---------------------------------Cite this article as: Huang JY, Kerns JR, Nute JL, Liu X, Stingo FC, Followill DS, Mirkovic D, Howell RM, Kry SF. Evaluation of three commercial metal artifact reduction methods for CT simulations in radiation therapy. Int J Cancer Ther Oncol 2014; 2(2):020224. DOI: 10.14319/ijcto.0202.2

Future vision for the quality assurance of oncology clinical trials

The National Cancer Institute clinical cooperative groups have been instrumental over the past 50 years in developing clinical trials and evidence-based process improvements for clinical oncology patient care. The cooperative groups are undergoing a transformation process as we further integrate molecular biology into personalized patient care and move to incorporate international partners in clinical trials. To support this vision, data acquisition and data management informatics tools must become both nimble and robust to support transformational research at an enterprise level. Information, including imaging, pathology, molecular biology, radiation oncology, surgery, systemic therapy, and patient outcome data needs to be integrated into the clinical trial charter using adaptive clinical trial mechanisms for design of the trial. This information needs to be made available to investigators using digital processes for real-time data analysis. Future clinical trials will need to be designed and completed in a timely manner facilitated by nimble informatics processes for data management. This paper discusses both past experience and future vision for clinical trials as we move to develop data management and quality assurance processes to meet the needs of the modern trial

Does quality of radiation therapy predict outcomes of multicenter cooperative group trials? A literature review

Central review of radiation therapy (RT) delivery within multicenter clinical trials was initiated in the early 1970s in the United States. Early quality assurance publications often focused on metrics related to process, logistics, and timing. Our objective was to review the available evidence supporting correlation of RT quality with clinical outcomes within cooperative group trials. A MEDLINE search was performed to identify multicenter studies that described central subjective assessment of RT protocol compliance (quality). Data abstracted included method of central review, definition of deviations, and clinical outcomes. Seventeen multicenter studies (1980-2012) were identified, plus one Patterns of Care Study. Disease sites were hematologic, head and neck, lung, breast, and pancreas. Between 0 and 97% of treatment plans received an overall grade of acceptable. In 7 trials, failure rates were significantly higher after inadequate versus adequate RT. Five of 9 and 2 of 5 trials reported significantly worse overall and progression-free survival after poor-quality RT, respectively. One reported a significant correlation, and 2 reported nonsignificant trends toward increased toxicity with noncompliant RT. Although more data are required, protocol-compliant RT may decrease failure rates and increase overall survival and likely contributes to the ability of collected data to answer the central trial question